View Post

Mature Data Drive New Insights With Novel Agents in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic. The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates (ADCs), and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic, explained Lisa A. Carey, MD, FASCO. …

View Post

An Expert Explains the Three Major Treatment Modalities in Triple Negative Breast Cancer

In In The News by Barbara Jacoby

By: Jessica Skarzynski From: curetoday.com “In the field of triple-negative breast cancer, we’re beginning to see some remarkable advances, mostly centering around the three paradigms that have become so attractive for the treatment of cancer: immunotherapy, targeted biologics and antibody-drug conjugates,” Dr. Howard A. “Skip” Burris, III said in an interview. When it comes to treating triple-negative breast cancer (TNBC), …

View Post

Clinical Challenges: ADCs and Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: medpagetoday.com The development of antibody drug conjugates adds a much needed option for women with TNBC Triple-negative breast cancer (TNBC) — i.e., breast cancer that does not express estrogen, progesterone, or HER2 receptors — comprises approximately 10%-20% of all breast cancers and represents “an unmet need in the field of breast oncology,” said Aditya Bardia, MD, …

View Post

Novel Approaches Push the Envelope in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jessica Hergert From: onclive.com Developments in antibody-drug conjugates (ADCs), TKIs, and neoadjuvant interventions are improving outcomes for patients with early- and advanced-stage HER2-positive breast cancer, said Douglas K. Marks, MD, adding that investigational approaches could expand the treatment armamentarium even further. “For the treating oncologists, the options to offer patients who previously had a very poor prognosis are becoming …

View Post

Drug to Replace Chemotherapy May Reshape Cancer Care

In In The News by Barbara Jacoby

By: Kanoko Matsuyama From: bloomberg.com * Promising treatment may reach far more breast cancer patients * Daiichi drug may outsell Roche’s Herceptin, spark dealmaking A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer …